| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02271295 Details | 2018-02-27 Interventional | 3 | 16 | Enoxaparin Fibrosis Cirrhosis | Premature discontinuation of inclusions by the sponsor for low inclusion - | |||
| NCT02223598 Details | 2018-02-27 Interventional | 1 | - | Dexamethasone Hematologic Neo… Multiple Myelom… Neoplasms Lymphoid Hemato… Relapsed and Re… | MTD determined - | |||
| NCT01919346 Details | 2018-02-27 Interventional | 2 | 21 | Eculizumab Delayed Graft F… Complement Acti… Kidney Transpla… | Based on results from Alexion PROTECT DGF study - | |||
| NCT03202446 Details | 2018-02-23 Interventional | 3 | 18 | Chitosan Cyclophosphamid… Breast Neoplasm… Breast Cancer S… Breast Cancer S… Breast Cancer, … | - - | |||
| NCT02371590 Details | 2018-02-23 Interventional | 2 | 0 | Lenalidomide Obinutuzumab Leukemia Leukemia, Lymph… Leukemia, Lymph… Chronic Lymphoc… | Study Not Activated Due to Contract Issues - | |||
| NCT01290601 Details | 2018-02-23 Interventional | 2 | 70 | Chloroquine Chloroquine dip… Primaquine Tafenoquine Malaria Plasmodium Viva… | Failure to meet pre-specified endpoint for the day 28 cure rate IDMC determined that Cohort 1 failed to meet specified endpoint for d28 cure rate; Cohort 2 wasn't initiated and follow-up in Cohort 1 should be completed according to protocol. Following last subjects last visit for Cohort 1 study was terminated. | |||
| NCT02498496 Details | 2018-02-22 Interventional | 4 | 0 | Magnesium Sulfa… Lung Diseases Lung Diseases, … Pulmonary Disea… | financing delays - | |||
| NCT01255163 Details | 2018-02-22 Interventional | 2 | 57 | Exenatide Alzheimer Disea… Cognitive Dysfu… Alzheimer's Dis… Mild Cognitive … | AstraZeneca withdrew support for the study. The study was terminated after AstraZeneca withdrew support. Early termination lead to small number of subjects analyzed. | |||
| NCT00268242 Details | 2018-02-22 Interventional | 2 | 24 | Gemcitabine Mitoxantrone Leukemia Leukemia, Myelo… Leukemia, Myelo… | If If 4 of 1st 10 or 10 of 1st 25 pts had unacceptable toxicity per protocol & Common Toxicity Criteria for Adverse Effects (CTCAE) v3.0 | |||
| NCT01936974 Details | 2018-02-20 Interventional | 2 | 7 | Bevacizumab Carboplatin Gemcitabine Oxaliplatin Carcinoma Fallopian Tube … Ovarian Carcino… Peritoneal Carc… | PI Decision - | |||
| NCT03081039 Details | 2018-02-19 Interventional | 3 | 0 | Carboplatin Gemcitabine Cholangiocarcin… Intrahepatic Ch… | Competing study - | |||
| NCT03036046 Details | 2018-02-15 Interventional | 1/2 | 0 | Fluconazole Olorofim Posaconazole Leukemia Acute Myeloid L… | Study no longer required - | |||
| NCT02856178 Details | 2018-02-15 Interventional | 1/2 | 0 | Caspofungin Olorofim Aspergillosis Invasive Pulmon… Leukemia Leukemia, Myelo… Leukemia, Myelo… Pulmonary Asper… Acute Myeloid L… Pulmonary Asper… | study no longer required - | |||
| NCT02578511 Details | 2018-02-15 Interventional | 1 | 0 | Ixazomib Acute Disease Leukemia Leukemia, Lymph… Lymphoma Lymphoma, Non-H… Pathologic Comp… Precursor Cell … Acute Lymphobla… Lymphoblastic L… Mixed Phenotype… | No enrollment, another competing study and difficult to find the right person to enroll on this
study. - | |||
| NCT00388700 Details | 2018-02-14 Interventional | 2 | 0 | Bevacizumab Fluorouracil Leucovorin Colorectal Neop… Colorectal Canc… | Financing and re-organization - | |||
| NCT00379912 Details | 2018-02-14 Interventional | 2 | [1 Refs] | 15 | Azacitidine Epoetin Alfa Myelodysplastic… Preleukemia Syndrome | Insufficient response rate Results of interim analysis led to early closure of the study. | ||
| NCT02120417 Details | 2018-02-13 Interventional | 2 | 149 | Capecitabine Breast Neoplasm… Breast Cancer | The study was terminated as other related studies of ruxolitinib did not provide sufficient
efficacy to warrant continuation. - | |||
| NCT02119663 Details | 2018-02-13 Interventional | 3 | 86 | Capecitabine Pancreatic Neop… Pancreatic Canc… | The safety committee found no safety issues but recommended halting the study based on a lack
of efficacy in a similar trial. The sponsor terminated the trial. The study was terminated prior to the final analysis at the recommendation of the Data Monitoring Committee based on the review of efficacy in the 18424-362 (JANUS 1). | |||
| NCT01601626 Details | 2018-02-13 Interventional | 2 | 71 | Ethambutol Isoniazid Lopinavir Pyrazinamide Pyridoxine Raltegravir Pot… Rifabutin Rifampin Ritonavir Vitamin B 6 Tuberculosis HIV Infection | The study was stopped early due to feasibility concerns. The study was terminated after 71 of 471 participants enrolled. Therefore, the study was under-powered and formal statistical comparisons between study arms were not undertaken as originally planned. Instead, summaries within study arm were provided. | |||
| NCT00878215 Details | 2018-02-13 Interventional | 2 | 40 | Liver Extracts Carcinoma, Hepa… Liver Neoplasms Hepatocellular … | The image-guidance system became commercially available - |